Omnio Healer AB is a pioneer company in combating inflammatory diseases, especially diabetic wounds, with novel drug candidates based on a series of conceptual breakthroughs in inflammation research.
The research founding the basis of Omnio Healer opens up a completely new therapeutic strategy for wound healing and anti-infection management. To reach a rapid clinical proof of concept, diabetic wound indications has been selected as the first to enter in the clinical development. Omnio Healer´s main project is currently at the gate to enter clinical development during 2013.
Since its foundation in 2006, Omnio Healer has assembled a network of expertise in science, development and management.
In 2011, the company has successfully been restructured and owned by the scientific founders. Currently the company has developed a comprehensive development strategy aiming at targeting diabetic wounds as the primary indication. |
|
